id,filing_uuid,filing_type,registrant_name,registrant_id,client_name,filing_year,filing_period,issue_code,specific_issues,government_entities,income_amount,expense_amount,is_no_activity,is_termination,received_date
1659396,0ae8782a-e4e9-4bc3-bcdd-ab34c71ec19d,Q1,"WILLIAMS AND JENSEN, PLLC",41454,GENENTECH INC,2015,first_quarter,MMM,Payment policies for prescription drugs.,"HOUSE OF REPRESENTATIVES,SENATE",40000,,0,0,2015-04-13T14:38:38.767000-04:00
1659397,0ae8782a-e4e9-4bc3-bcdd-ab34c71ec19d,Q1,"WILLIAMS AND JENSEN, PLLC",41454,GENENTECH INC,2015,first_quarter,TAX,General tax issues.,"HOUSE OF REPRESENTATIVES,SENATE",40000,,0,0,2015-04-13T14:38:38.767000-04:00
1659398,0ae8782a-e4e9-4bc3-bcdd-ab34c71ec19d,Q1,"WILLIAMS AND JENSEN, PLLC",41454,GENENTECH INC,2015,first_quarter,HCR,"21st Century Cures Initiative (House Energy and Commerce Committee) and Innovation for Healthier Americans (Senate HELP Committee); Potential pharmaceutical provisions in House Budget Resolution (H. Con. Res. 27) and Senate Budget Resolution (S. Con. Res. 11 ); Possible drug provisions in H.R. 2, the Medicare Access and CHIP Reauthorization Act; issues concerning clinical trials; issues concerning drug compounding; Implementation of Patient Protection and Affordable Care Act; Drug pricing under 340B program.","HOUSE OF REPRESENTATIVES,SENATE",40000,,0,0,2015-04-13T14:38:38.767000-04:00